Migalastat Versus Enzyme Replacement Therapy in Treatment‐Naïve F abry Disease: Real‐World Evidence From the followME F abry Pathfinders Registry
Journal of Inherited Metabolic Disease · 2026-11 · 49 (6)
DOI: 10.1002/jimd.70261 ↗Abstract
ABSTRACT Fabry disease is a rare, progressive, X‐linked disease resulting from α‐galactosidase A enzyme deficiency due to GLA gene variants. Current treatments include intravenous enzyme replacement therapy (ERT) and the oral pharmacologic chaperone migalastat. The followME Fabry Pathfinders registry (EUPAS20599) is an ongoing prospective patient registry evaluating outcomes for Fabry treatments. The present analyses compared the effectiveness of migalastat with ERT in treatment‐naïve patients ≥ 16 years at enrollment. The prespecified primary outcome was Fabry‐associated clinical event (FACE) rates/1000 person‐years from treatment start. Secondary outcomes included estimated glomerular filtration rate (eGFR) annualized rate of change, proportion of patients with FACEs, FACE incidence rates, and time to first FACE. The populations included 319 migalastat‐ and 140 ERT‐treated patients for FACE analyses; 268 and 119, respectively, for eGFR CKD‐EPI outcomes. Propensity score matching (1:1, nearest neighbor with replacement) balanced treatment groups with absolute standardized mean differences < 0.1 after matching for baseline age, sex and eGFR (matching for amenability status was not possible). Overall, patients experienced 55.3 FACEs/1000 patient‐years (95% confidence interval [CI] 40.7, 75.3) with migalastat and 100.7 (53.7, 188.9) with ERT; the event‐rate ratio was 0.55 (0.27, 1.11; p = 0.093). The event‐rate ratio (95% CI) for cerebrovascular FACEs was 0.24 (0.06, 0.88; unadjusted p = 0.031 ; Benjamini‐Hochberg‐adjusted p = 0.093), representing 4.7 (2.0, 11.2) FACEs/1000 patient‐years with migalastat and 19.8 (7.5, 52.4) with ERT. eGFR CKD‐EPI slope, mL/min/1.73 m 2 /year (95% CI), was −1.47 (−2.17, −0.77) with migalastat and −2.50 (−3.53, −1.46) with ERT. Comparisons generally numerically favored migalastat over ERT, with cerebrovascular FACEs being statistically significant when not adjusting for multiple comparisons. These analyses support real‐world multisystemic effectiveness of migalastat in Fabry disease.
EUVIMED